| Year |
Citation |
Score |
| 2019 |
Minn I, Huss DJ, Ahn HH, Chinn TM, Park A, Jones J, Brummet M, Rowe SP, Sysa-Shah P, Du Y, Levitsky HI, Pomper MG. Imaging CAR T cell therapy with PSMA-targeted positron emission tomography. Science Advances. 5: eaaw5096. PMID 31281894 DOI: 10.1126/Sciadv.Aaw5096 |
0.503 |
|
| 2018 |
Hoves S, Ooi CH, Wolter C, Sade H, Bissinger S, Schmittnaegel M, Ast O, Giusti AM, Wartha K, Runza V, Xu W, Kienast Y, Cannarile MA, Levitsky H, Romagnoli S, et al. Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. The Journal of Experimental Medicine. PMID 29436396 DOI: 10.1084/Jem.20171440 |
0.564 |
|
| 2016 |
Fu H, Wang J, Fu J, Jones RJ, Levitsky H, Fuchs EJ. Tumor Antigen Vaccination of Donors to Augment Graft-Versus-Tumor Effects after Allogeneic Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide Blood. 128: 499-499. DOI: 10.1182/Blood.V128.22.499.499 |
0.627 |
|
| 2015 |
Kadayakkara DK, Korrer MJ, Bulte JW, Levitsky HI. Paradoxical decrease in the capture and lymph node delivery of cancer vaccine antigen induced by a TLR4 agonist as visualized by dual-mode imaging. Cancer Research. 75: 51-61. PMID 25388285 DOI: 10.1158/0008-5472.CAN-14-0820 |
0.346 |
|
| 2015 |
Cannarile M, Hoves S, Broeske A, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, Jones T, Jucknischke U, Scheiblich S, Gorr IH, Walz A, ... ... Levitsky H, et al. Abstract PR04: Targeting tumor-asoociated macrophages with a novel anti-CSF1R antibody in cancer patients Cancer Research. 75. DOI: 10.1158/1538-7445.Chtme14-Pr04 |
0.544 |
|
| 2015 |
Agarwal M, Saint-Fleur A, Fu J, Levitsky H, Trimble CL. Abstract 4048: HPV16 immunity induced by immune responses to mutations in E6 and E7 proteins Cancer Research. 75: 4048-4048. DOI: 10.1158/1538-7445.Am2015-4048 |
0.398 |
|
| 2015 |
Fu H, Fu J, Wang J, Jones RJ, Fuchs E, Levitsky H. Abstract 1351: Post-transplantation cyclophosphamide depletes vaccine primed donor T cells and compromises graft-versus-tumor effects in alloBMT model Immunology. 75: 1351-1351. DOI: 10.1158/1538-7445.Am2015-1351 |
0.509 |
|
| 2015 |
Prince G, Thoburn C, Warlick E, Hess A, Levitsky H, Smith B. 55 IN VIVO OLIGOCLONAL T-CELL EXPANSION AND SPECIFIC IN VITRO T-CELL RESPONSES FOLLOWING K562/GM-CSF VACCINATION OF MDS PATIENTS Leukemia Research. 39: S26. DOI: 10.1016/S0145-2126(15)30056-4 |
0.417 |
|
| 2014 |
Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, Jones T, Jucknischke U, Scheiblich S, Kaluza K, Gorr IH, ... ... Levitsky H, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 25: 846-59. PMID 24898549 DOI: 10.1016/J.Ccr.2014.05.016 |
0.474 |
|
| 2013 |
Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, Brody J, Luong R, Rosenblum MD, Steinman L, Levitsky HI, Tse V, et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. The Journal of Clinical Investigation. 123: 2447-63. PMID 23728179 DOI: 10.1172/Jci73340 |
0.471 |
|
| 2012 |
Zhou G, Levitsky H. Towards curative cancer immunotherapy: overcoming posttherapy tumor escape. Clinical & Developmental Immunology. 2012: 124187. PMID 22778760 DOI: 10.1155/2012/124187 |
0.477 |
|
| 2012 |
marabelle a, Kohrt H, Brody J, Torchia J, rajapaksa r, Luong R, Zhou G, Levitsky H, Tse V, Levy R. Abstract LB-139: In situ Treg immunomodulation at a single tumor site with CpG and immune checkpoint antibodies cures metastatic disease Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-139 |
0.562 |
|
| 2011 |
Gladstone DE, Bolaños-Meade J, Huff CA, Zahurak M, Flinn I, Borrello I, Luznik L, Fuchs E, Kasamon Y, Matsui W, Powell J, Levitsky H, Brodsky RA, Ambinder R, Jones RJ, et al. High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas. Leukemia & Lymphoma. 52: 2076-81. PMID 21756035 DOI: 10.3109/10428194.2011.594191 |
0.363 |
|
| 2011 |
Zhou G, Ding ZC, Fu J, Levitsky HI. Presentation of acquired peptide-MHC class II ligands by CD4+ regulatory T cells or helper cells differentially regulates antigen-specific CD4+ T cell response. Journal of Immunology (Baltimore, Md. : 1950). 186: 2148-55. PMID 21242518 DOI: 10.4049/jimmunol.1002917 |
0.478 |
|
| 2011 |
Gerber JM, Qin L, Kowalski J, Smith BD, Griffin CA, Vala MS, Collector MI, Perkins B, Zahurak M, Matsui W, Gocke CD, Sharkis SJ, Levitsky HI, Jones RJ. Characterization of chronic myeloid leukemia stem cells. American Journal of Hematology. 86: 31-7. PMID 21132730 DOI: 10.1002/Ajh.21915 |
0.35 |
|
| 2011 |
Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Pawelec G, Roep BO, Romero P, Hoos A, et al. Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunology, Immunotherapy : Cii. 60: 15-22. PMID 21080166 DOI: 10.1007/S00262-010-0940-Z |
0.3 |
|
| 2011 |
Kanakry CG, Hess AD, Gocke CD, Thoburn C, Kos F, Meyer C, Briel J, Luznik L, Smith BD, Levitsky H, Karp JE. Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells. Blood. 117: 608-17. PMID 20935254 DOI: 10.1182/Blood-2010-04-277939 |
0.554 |
|
| 2011 |
Symons HJ, Kesserwan C, Kos F, Thoburn CJ, Munchel AT, Ying W, Luznik L, Levitsky HI, Jones RJ, Hess AD, Fuchs EJ. Favorable Immune Reconstitution After Nonmyeloablative, T-Cell Replete, HLA-Haploidentical BMT with Post-Transplant Cyclophosphamide Blood. 118: 1009-1009. DOI: 10.1182/BLOOD.V118.21.1009.1009 |
0.439 |
|
| 2011 |
Kesserwan C, Munchel A, Kos F, Thoburn C, Hess A, Luznik L, Kasamon Y, Levitsky H, Jones R, Fuchs E, Symons H. Immune Reconstitution After Nonmyeloablative, T-Cell Replete, HLA-Haploidentical BMT With Post-Transplantation Cyclophosphamide Biology of Blood and Marrow Transplantation. 17: S230-S231. DOI: 10.1016/J.Bbmt.2010.12.237 |
0.485 |
|
| 2010 |
Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy K, Miller CB, Garrett-Mayer E, Tsai HL, Qin L, Chia C, Biedrzycki B, Harding TC, Tu GH, Jones R, Hege K, ... Levitsky HI, et al. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 338-47. PMID 20048335 DOI: 10.1158/1078-0432.Ccr-09-2046 |
0.308 |
|
| 2009 |
Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJ, Old LJ, Romero P, Hoos A, Davis MM. "MIATA"-minimal information about T cell assays. Immunity. 31: 527-8. PMID 19833080 DOI: 10.1016/J.Immuni.2009.09.007 |
0.32 |
|
| 2009 |
Bohana-Kashtan O, Morisot S, Hildreth R, Brayton C, Levitsky HI, Civin CI. Selective reduction of graft-versus-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligand. Journal of Immunology (Baltimore, Md. : 1950). 183: 696-705. PMID 19535642 DOI: 10.4049/Jimmunol.0800561 |
0.488 |
|
| 2009 |
Long CM, van Laarhoven HW, Bulte JW, Levitsky HI. Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes. Cancer Research. 69: 3180-7. PMID 19276358 DOI: 10.1158/0008-5472.CAN-08-3691 |
0.447 |
|
| 2008 |
Rabinovich BA, Ye Y, Etto T, Chen JQ, Levitsky HI, Overwijk WW, Cooper LJ, Gelovani J, Hwu P. Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proceedings of the National Academy of Sciences of the United States of America. 105: 14342-6. PMID 18794521 DOI: 10.1073/Pnas.0804105105 |
0.52 |
|
| 2008 |
Symons HJ, Levy MY, Wang J, Zhou X, Zhou G, Cohen SE, Luznik L, Levitsky HI, Fuchs EJ. The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 14: 499-509. PMID 18410892 DOI: 10.1016/j.bbmt.2008.02.013 |
0.547 |
|
| 2008 |
Mirmonsef P, Tan G, Zhou G, Morino T, Noonan K, Borrello I, Levitsky HI. Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation. Blood. 111: 2112-21. PMID 18063750 DOI: 10.1182/Blood-2007-06-096586 |
0.763 |
|
| 2008 |
Hess AD, Meyer C, Thoburn C, Kos F, Gocke C, Levitsky H, Karp J. Immune Recovery after Timed Sequential Therapy in Acute Myelogenous Leukemia: Discordant Recovery of Naïve T Lymphocytes and Antigen Driven Regulatory T Cells. Blood. 112: 947-947. DOI: 10.1182/Blood.V112.11.947.947 |
0.582 |
|
| 2007 |
Finke LH, Wentworth K, Blumenstein B, Rudolph NS, Levitsky H, Hoos A. Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine. 25: B97-B109. PMID 17916465 DOI: 10.1016/J.Vaccine.2007.06.067 |
0.327 |
|
| 2007 |
Zhou G, Levitsky HI. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. Journal of Immunology (Baltimore, Md. : 1950). 178: 2155-62. PMID 17277120 |
0.608 |
|
| 2007 |
Meyer CF, Thoburn C, Kos F, Gocke C, Levitsky HI, Briel JA, Hess A, Karp JE. Characterization of Immune Reconstitution Following High Dose Chemotherapy in Acute Myeloid Leukemia. Blood. 110: 3888-3888. DOI: 10.1182/blood.v110.11.3888.3888 |
0.447 |
|
| 2007 |
Bohana-Kashtan O, Levitsky H, Civin CI. Identification of New Alloantigen-Reactive CD8+ Cytotoxic and Suppressor T Cell Subpopulations. Blood. 110: 3229-3229. DOI: 10.1182/Blood.V110.11.3229.3229 |
0.595 |
|
| 2006 |
Walczak P, Ruiz-Cabello J, Kedziorek DA, Gilad AA, Lin S, Barnett B, Qin L, Levitsky H, Bulte JW. Magnetoelectroporation: improved labeling of neural stem cells and leukocytes for cellular magnetic resonance imaging using a single FDA-approved agent. Nanomedicine : Nanotechnology, Biology, and Medicine. 2: 89-94. PMID 17292120 DOI: 10.1016/J.Nano.2006.01.003 |
0.325 |
|
| 2006 |
Hung CF, Tsai YC, He L, Coukos G, Fodor I, Qin L, Levitsky H, Wu TC. Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice. Gene Therapy. 14: 20-9. PMID 16915291 DOI: 10.1038/Sj.Gt.3302840 |
0.4 |
|
| 2006 |
Horna P, Cuenca A, Cheng F, Brayer J, Wang HW, Borrello I, Levitsky H, Sotomayor EM. In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity. Blood. 107: 2871-8. PMID 16339406 DOI: 10.1182/Blood-2005-07-3014 |
0.59 |
|
| 2006 |
Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood. 107: 628-36. PMID 16179369 DOI: 10.1182/blood-2005-07-2737 |
0.667 |
|
| 2006 |
Kashtan O, Levitsky HI, Civin CI. Ex Vivo Fas Ligand Treatment Selectively Eliminates T Cells That Mediate GVHD. Blood. 108: 3167-3167. DOI: 10.1182/Blood.V108.11.3167.3167 |
0.486 |
|
| 2006 |
Bohana-Kashtan O, Levitsky HI, Civin CI. 770. Selective Elimination of Alloreactive GVHD-Mediating Donor T Cells by Ex Vivo sFasL Treatment Molecular Therapy. 13: S298. DOI: 10.1016/J.Ymthe.2006.08.855 |
0.517 |
|
| 2005 |
Noonan K, Matsui W, Serafini P, Carbley R, Tan G, Khalili J, Bonyhadi M, Levitsky H, Whartenby K, Borrello I. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Research. 65: 2026-34. PMID 15753403 DOI: 10.1158/0008-5472.Can-04-3337 |
0.815 |
|
| 2005 |
Borrello I, Levitsky H, Damon L, Linker C, Deangelo D, Alyea E, Stock W, Sher D, Donnelly A, Hege K. Vaccine-associated immune and WT-1 responses are associated with better relapse-free survival in patients with AML in remission treated with a GM-CSF secreting leukemia vaccine and autologous stem cell transplant (ASCT) Journal of Clinical Oncology. 23: 6539-6539. DOI: 10.1200/Jco.2005.23.16_Suppl.6539 |
0.443 |
|
| 2005 |
Chia CY, Smith BD, Kasamon Y, Miller CB, Brummet ME, Bankova L, Kowalski J, Biedrzycki B, Hege K, Beck LA, Levitsky H. Characterization of Vaccine Site and Cellular Infiltrate in Subjects with Chronic Myeloid Leukemia (CML) Receiving K562/GM-CSF Vaccination in Combination with Imatinib Mesylate with or without Topical Imiquimod. Blood. 106: 2399-2399. DOI: 10.1182/Blood.V106.11.2399.2399 |
0.447 |
|
| 2004 |
Zhou G, Lu Z, McCadden JD, Levitsky HI, Marson AL. Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. The Journal of Experimental Medicine. 200: 1581-92. PMID 15596524 DOI: 10.1084/jem.20041240 |
0.817 |
|
| 2004 |
Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI, Powell JD, Pardoll DM, Drake CG, Vignali DA. Role of LAG-3 in regulatory T cells. Immunity. 21: 503-13. PMID 15485628 DOI: 10.1016/J.Immuni.2004.08.010 |
0.759 |
|
| 2004 |
Kast WM, Levitsky H, Marincola FM. Synopsis of the 6th Walker's Cay Colloquium on Cancer Vaccines and Immunotherapy. Journal of Translational Medicine. 2: 20. PMID 15212694 DOI: 10.1186/1479-5876-2-20 |
0.463 |
|
| 2004 |
Stock W, Levitsky HI, Borrello IM, Sher D, Deangelo DJ, Alyea EP, Damon LE, Linker CA, Hege K. Posttransplant immunotherapy with a GM-CSF-based tumor vaccine following autologous stem cell transplant (ASCT) for acute myeloid leukemia (AML) Journal of Clinical Oncology. 22: 6545-6545. DOI: 10.1200/JCO.2004.22.14_SUPPL.6545 |
0.355 |
|
| 2003 |
Cuenca A, Cheng F, Wang H, Brayer J, Horna P, Gu L, Bien H, Borrello IM, Levitsky HI, Sotomayor EM. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Research. 63: 9007-15. PMID 14695219 |
0.595 |
|
| 2003 |
Cui Y, Kelleher E, Straley E, Fuchs E, Gorski K, Levitsky H, Borrello I, Civin CI, Schoenberger SP, Cheng L, Pardoll DM, Whartenby KA. Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem cells. Nature Medicine. 9: 952-8. PMID 12778137 DOI: 10.1038/Nm882 |
0.796 |
|
| 2003 |
Luznik L, Slansky JE, Jalla S, Borrello I, Levitsky HI, Pardoll DM, Fuchs EJ. Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood. 101: 1645-52. PMID 12406877 DOI: 10.1182/Blood-2002-07-2233 |
0.662 |
|
| 2002 |
Housseau F, Langer DA, Oberholtzer SD, Moorthy A, Levitsky HI, Pardoll DM, Topalian SL. Tumor-specific CD8+ T lymphocytes derived from the peripheral blood of prostate cancer patients by in vitro stimulation with autologous tumor cell lines. International Journal of Cancer. Journal International Du Cancer. 98: 57-62. PMID 11857386 DOI: 10.1002/Ijc.10154 |
0.599 |
|
| 2001 |
Sotomayor EM, Borrello I, Rattis FM, Cuenca AG, Abrams J, Staveley-O'Carroll K, Levitsky HI. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression Blood. 98: 1070-1077. PMID 11493453 DOI: 10.1182/Blood.V98.4.1070 |
0.612 |
|
| 2001 |
Wu B, Wu JM, Miagkov A, Adams RN, Levitsky HI, Drachman DB. Specific immunotherapy by genetically engineered APCs: the "guided missile" strategy. Journal of Immunology (Baltimore, Md. : 1950). 166: 4773-9. PMID 11254740 DOI: 10.4049/JIMMUNOL.166.7.4773 |
0.339 |
|
| 2001 |
Levitsky H. T cells to go Blood. 98: 503-503. DOI: 10.1182/Blood.V98.3.503 |
0.596 |
|
| 2000 |
Gorin NC, Estey E, Jones RJ, Levitsky HI, Borrello I, Slavin S. New Developments in the Therapy of Acute Myelocytic Leukemia. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 69-89. PMID 11701536 |
0.37 |
|
| 2000 |
Borrello I, Sotomayor EM, Rattis FM, Cooke SK, Gu L, Levitsky HI. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)- producing tumor vaccines Blood. 95: 3011-3019. PMID 10807763 DOI: 10.1182/Blood.V95.10.3011.010K15_3011_3019 |
0.512 |
|
| 2000 |
Lu Z, Yuan L, Zhou X, Sotomayor E, Levitsky HI, Pardoll DM. CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes. The Journal of Experimental Medicine. 191: 541-50. PMID 10662799 DOI: 10.1084/Jem.191.3.541 |
0.773 |
|
| 1999 |
Sotomayor EM, Borrello I, Tubb E, Allison JP, Levitsky HI. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance Proceedings of the National Academy of Sciences of the United States of America. 96: 11476-11481. PMID 10500201 DOI: 10.1073/Pnas.96.20.11476 |
0.608 |
|
| 1999 |
Borrello I, Sotomayor EM, Cooke S, Levitsky HI. A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell- based vaccines Human Gene Therapy. 10: 1983-1991. PMID 10466632 DOI: 10.1089/10430349950017347 |
0.464 |
|
| 1999 |
Sotomayor EM, Borrello I, Tubb E, Rattis FM, Bien H, Lu Z, Fein S, Schoenberger S, Levitsky HI. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nature Medicine. 5: 780-7. PMID 10395323 DOI: 10.1038/10503 |
0.832 |
|
| 1999 |
Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. The Journal of Experimental Medicine. 188: 2357-68. PMID 9858522 DOI: 10.1084/Jem.188.12.2357 |
0.666 |
|
| 1998 |
Nigam A, Yacavone RF, Zahurak ML, Johns CM, Pardoll DM, Piantadosi S, Levitsky HI, Nelson WG. Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. International Journal of Oncology. 12: 161-70. PMID 9454900 DOI: 10.3892/Ijo.12.1.161 |
0.51 |
|
| 1998 |
Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, Levitsky H. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proceedings of the National Academy of Sciences of the United States of America. 95: 1178-83. PMID 9448305 DOI: 10.1073/Pnas.95.3.1178 |
0.76 |
|
| 1997 |
Levitsky HI. Tumors derived from antigen presenting cells. Seminars in Immunology. 8: 281-7. PMID 8956456 DOI: 10.1006/smim.1996.0036 |
0.607 |
|
| 1996 |
Sotomayor EM, Borrello I, Levitsky HI. Tolerance and cancer: A critical issue in tumor immunology Critical Reviews in Oncogenesis. 7: 433-456. PMID 9467666 DOI: 10.1615/Critrevoncog.V7.I5-6.30 |
0.546 |
|
| 1996 |
Jaffee EM, Thomas MC, Huang AY, Hauda KM, Levitsky HI, Pardoll DM. Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 19: 176-83. PMID 8811492 DOI: 10.1097/00002371-199605000-00002 |
0.319 |
|
| 1996 |
Huang AY, Bruce AT, Pardoll DM, Levitsky HI. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? The Journal of Experimental Medicine. 183: 769-76. PMID 8642281 DOI: 10.1084/Jem.183.3.769 |
0.657 |
|
| 1996 |
Huang AY, Bruce AT, Pardoll DM, Levitsky HI. In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity. 4: 349-55. PMID 8612129 DOI: 10.1016/S1074-7613(00)80248-4 |
0.502 |
|
| 1996 |
Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Research. 56: 21-6. PMID 8548765 |
0.789 |
|
| 1995 |
Jaffee EM, Lazenby A, Meurer J, Marshall F, Hauda KM, Counts C, Hurwitz H, Simons JW, Levitsky HI, Pardoll DM. Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 18: 1-9. PMID 8535565 DOI: 10.1097/00002371-199507000-00001 |
0.351 |
|
| 1995 |
Wu TC, Guarnieri FG, Staveley-O'Carroll KF, Viscidi RP, Levitsky HI, Hedrick L, Cho KR, August JT, Pardoll DM. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proceedings of the National Academy of Sciences of the United States of America. 92: 11671-5. PMID 8524826 DOI: 10.1073/Pnas.92.25.11671 |
0.717 |
|
| 1995 |
Berns AJ, Clift S, Cohen LK, Donehower RC, Dranoff G, Hauda KM, Jaffee EM, Lazenby AJ, Levitsky HI, Marshall FF. Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Human Gene Therapy. 6: 347-68. PMID 7779918 DOI: 10.1089/Hum.1995.6.3-347 |
0.311 |
|
| 1995 |
Wu TC, Huang AY, Jaffee EM, Levitsky HI, Pardoll DM. A reassessment of the role of B7-1 expression in tumor rejection. The Journal of Experimental Medicine. 182: 1415-21. PMID 7595212 DOI: 10.1084/Jem.182.5.1415 |
0.453 |
|
| 1994 |
Golumbek P, Levitsky H, Jaffee L, Pardoll DM. The antitumor immune response as a problem of self-nonself discrimination: implications for immunotherapy. Immunologic Research. 12: 183-92. PMID 8254226 DOI: 10.1007/Bf02918303 |
0.677 |
|
| 1994 |
Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. The Journal of Experimental Medicine. 179: 1215-24. PMID 7908321 DOI: 10.1084/Jem.179.4.1215 |
0.693 |
|
| 1994 |
Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Bone marrow-derived cells present MHC class I-restricted tumour antigens in priming of antitumour immune responses. Ciba Foundation Symposium. 187: 229-40; discussion 2. PMID 7796673 DOI: 10.1002/9780470514672.ch15 |
0.395 |
|
| 1994 |
Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (New York, N.Y.). 264: 961-5. PMID 7513904 DOI: 10.1126/Science.7513904 |
0.635 |
|
| 1993 |
Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proceedings of the National Academy of Sciences of the United States of America. 90: 3539-43. PMID 8097319 DOI: 10.1073/Pnas.90.8.3539 |
0.596 |
|
| 1993 |
Golumbek PT, Hamzeh FM, Jaffee EM, Levitsky H, Lietman PS, Pardoll DM. Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines. Journal of Immunotherapy : Official Journal of the Society For Biological Therapy. 12: 224-30. PMID 1335754 DOI: 10.1097/00002371-199211000-00002 |
0.659 |
|
| 1992 |
Pardoll D, Golumbek P, Jaffee L, Levitsky H, Dranoff G, Mulligan R. MOLECULAR ENGINEERING OF THE ANTITUMOR IMMUNE RESPONSE Journal of Immunotherapy. 11: 137. DOI: 10.1097/00002371-199202000-00044 |
0.417 |
|
| 1991 |
Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, Pardoll DM. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science (New York, N.Y.). 254: 713-6. PMID 1948050 DOI: 10.1126/science.1948050 |
0.531 |
|
| Show low-probability matches. |